How Global Medtech Shifts Are Reshaping South Asia's Device Economy

Volume-based procurement, site-of-care migration, supply chain reconfiguration, GLP-1 adoption and platform competition are redefining how medical technology is priced, produced and adopted — with direct consequences for South Asia.

Executive Summary

Global medical technology is entering a period of accelerated structural change. Analysis from Clarivate's Medtech Trends to Watch 2026 identifies five forces reshaping competition: China's expanding national volume-based procurement (VBP) programme, the migration of procedures into outpatient and ambulatory surgical centre (ASC) settings, tariff and geopolitics-driven supply chain reconfiguration, the rapid adoption of GLP-1 receptor agonists, and a shift toward platform-based competition built on robotics, imaging, navigation and digital workflow software.

South Asia sits on both sides of these shifts. The region remains a substantial net importer of high-end imaging systems, surgical robotics and advanced implantables, which leaves its health systems and procurement agencies exposed to global pricing decisions made elsewhere. Simultaneously, a combination of industrial policy support, engineering depth and expanding digital public infrastructure positions several South Asian economies to capture a larger share of device manufacturing, software and services value.

The strategic question for the region is no longer whether to participate in global medtech supply chains, but in which segments — and on what terms.

Introduction

The global medical device industry has historically been shaped by clinical innovation cycles. That is changing. Pricing architecture, reimbursement rules, trade policy and manufacturing geography now move markets as forcefully as product launches do.

The Clarivate analysis captures this reordering. China's VBP programme, originally intended to widen patient access and moderate device costs, has evolved into a market-structuring mechanism with increasingly sophisticated price-anchoring rules and allocation systems that favour domestic manufacturers. The consequence, as the report notes, is that VBP is no longer a purely local policy: it is influencing expectations around price, volume and competitive positioning well beyond China's borders.

For South Asia — home to some of the world's largest public procurement programmes, a fast-expanding private hospital sector and a rapidly growing chronic disease burden — these developments are not abstract. They set reference prices, shape multinational portfolio priorities and determine where manufacturing capacity is built next.

Main Analysis

#### 1. Pricing pressure and the procurement template

China's latest national VBP round introduces deeper price compression and allocation systems designed to support domestic suppliers. Multinational manufacturers now weigh participation in China against margin discipline elsewhere, and that calculus influences everything from product launch sequencing to regional pricing corridors.

South Asian procurement agencies operate under comparable pressure. Public health systems in the region face persistent constraints on capital budgets and reimbursement ceilings, and procurement is increasingly centralised and price-focused. Where large-volume device categories are tendered, buyers reference global price benchmarks. A lower global reference price is generally positive for access and for payers, but it can narrow the commercial case for introducing premium technologies into markets that are still building capacity.

The practical implication is that South Asia may see earlier, faster adoption of cost-reduced versions of established device categories — and slower, more selective adoption of the newest high-acuity platforms — unless reimbursement pathways evolve in parallel.

#### 2. The migration of procedures to lower-cost settings

The continued movement of procedures out of inpatient hospitals into outpatient departments and ASCs is one of the most consequential trends in global device strategy. The US Centers for Medicare & Medicaid Services' 2026 outpatient and ASC payment rules reinforce the shift by expanding the ASC covered procedure list and phasing out the inpatient-only list, opening the door for higher-acuity procedures such as cardiac ablation to migrate to lower-cost settings where clinically appropriate.

This pattern has direct relevance for South Asia, where cost containment and capacity constraints make day-care and short-stay surgical models attractive. Device requirements change as procedures move: smaller footprints, portability, single-use or easily sterilised components, simplified user interfaces and remote support become more important than in a tertiary hospital setting. Manufacturers that design for these environments — rather than adapting inpatient platforms — are likely to find more receptive buyers across the region.

#### 3. Supply chain reconfiguration and the manufacturing opening

Tariff exposure, geopolitical tension and volatile input costs are challenging long-standing assumptions about where devices are produced. The Clarivate analysis notes that manufacturers are diversifying sourcing, revisiting business strategies and building more flexible multi-region manufacturing footprints, while larger players use scale, vertical integration and technology investment to absorb volatility.

This is the most tangible opportunity for South Asia. India's medical device sector has expanded through a combination of industrial incentive programmes and dedicated manufacturing clusters, and states have competed to host device parks and component suppliers. The region's engineering and electronics capabilities — built through automotive, consumer electronics and pharmaceutical manufacturing — are transferable to device assembly, precision components, electronics modules and single-use consumables.

The constraint is not labour or land cost. It is quality-system maturity, regulatory equivalence, clinical validation capacity and depth of supplier ecosystems for specialised materials. Moving from assembly to design authority is a multi-year process, not a policy announcement.

#### 4. GLP-1 therapies and shifting care pathways

The rapid adoption of GLP-1 receptor agonists is altering how clinicians and patients approach weight management and related comorbidities. The Clarivate analysis notes that while bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1 therapies have changed referral patterns and are producing uneven volume pressure across bariatric procedures, with downstream effects emerging in diabetes care, sleep apnea management and cardiovascular monitoring.

South Asia carries a substantial share of the global metabolic disease burden, and access to these therapies is constrained by price, supply and prescribing infrastructure. As patents on some molecules expire and competition intensifies, affordability could improve — which would shift device demand across obesity, bariatric, diabetes and cardiac monitoring categories in ways that are difficult to forecast from historical procedure volumes alone.

For regional manufacturers and distributors, the strategic task is portfolio flexibility: categories tied to metabolic disease management may grow in diagnostics and monitoring even as some surgical volumes soften.

#### 5. Platform competition and enabling technologies

Robotics, imaging, navigation and digital workflow software are no longer adjuncts to procedures; they are becoming the architecture around which service lines are organised. Manufacturers are investing in platform systems that anchor clinical planning, surgical execution and postoperative care, and open-platform approaches are introducing new competitive dynamics.

South Asia's advantage here is less in hardware and more in software, data and services. Expanding digital health infrastructure — including national health ID and health records programmes in India — creates the data rails on which workflow tools, imaging analytics and AI-assisted diagnostics can be built. Teleradiology and remote clinical support already address specialist shortages in smaller cities and rural districts, and demand for these services is likely to grow.

The constraint is regulatory and clinical validation capacity. Software-as-a-medical-device pathways, clinical evidence requirements and data governance frameworks remain uneven across the region.

Regional Impact

The five trends interact differently across South Asian economies.

On economic growth and industrial development, device manufacturing and component supply represent a realistic diversification path, complementing pharmaceuticals and electronics. Employment gains are likely to be concentrated in skilled technical roles rather than large-scale assembly.

On trade integration and regional cooperation, medical devices remain one of the least harmonised product categories in South Asia. Divergent registration requirements, testing standards and labelling rules raise costs for manufacturers serving multiple markets. Progress on mutual recognition — under SAARC, BIMSTEC or bilateral arrangements — would materially improve regional competitiveness.

On foreign investment, supply chain diversification is drawing multinational interest in local manufacturing, joint ventures and contract development. Investment is more likely to flow toward proven quality systems and export-ready facilities than toward greenfield capacity serving only domestic demand.

On technology adoption and innovation ecosystems, platform-based competition favours regions with strong software talent, clinical research capacity and regulatory clarity. Without those, South Asia risks remaining a deployment market for systems designed elsewhere.

On supply chain resilience and financial inclusion, device affordability remains the binding constraint. Expanding health insurance coverage broadens the addressable market but also intensifies procurement price pressure.

Strategic Insights

For multinational manufacturers, South Asia is shifting from a distribution territory to a supply and engineering location. Localisation of manufacturing and R&D is increasingly a condition of access to large public procurement, not merely a cost decision.

For regional manufacturers, the credible route upward runs through quality certification, export-market registration and component specialisation — particularly in electronics modules, precision plastics and single-use consumables — rather than competing head-on with global platform vendors.

For investors, the most durable opportunities sit in enabling infrastructure: contract manufacturing, sterilisation and testing services, cold chain and logistics, device software, and clinical data services.

For policymakers, three priorities stand out: harmonising device regulation to reduce cross-border friction; building clinical evaluation and testing capacity so that local products can be validated credibly; and designing reimbursement pathways that reward value rather than only lowest price.

Competitive risks are equally clear. Aggressive price compression can narrow the supplier base over time, reducing resilience. Over-reliance on imported high-end platforms leaves health systems exposed to tariff and freight shocks. And an underdeveloped regulatory apparatus can slow the introduction of genuinely useful technologies.

Future Outlook

Over the next three to five years, several developments appear likely.

Pricing and procurement will remain the dominant force in emerging markets, with volume-based models spreading in form if not in name. Regional buyers will increasingly benchmark against international reference prices.

Manufacturing capacity in South Asia is expected to broaden beyond consumables into imaging components, orthopaedic and cardiovascular device assembly, and electronics-intensive diagnostics, supported by incentive programmes and cluster development.

Artificial intelligence and digital health will move from pilot deployments toward embedded clinical workflows, with the strongest traction in imaging triage, remote monitoring and hospital operations — subject to regulatory maturation.

Trade integration may advance incrementally, most plausibly through bilateral regulatory cooperation and industry-led standards alignment rather than comprehensive regional agreements.

Energy transition and sustainability considerations will shape manufacturing decisions, as device production faces pressure on energy intensity, packaging waste and single-use plastics.

Investment is likely to concentrate in companies with export capability and validated quality systems, with private capital playing a larger role in scaling mid-sized manufacturers and device software firms.

South Asia's global competitiveness in medical technology will ultimately depend less on cost advantage and more on regulatory credibility, clinical evidence generation and the ability to integrate hardware with software and services.

Conclusion

The forces identified in Clarivate's 2026 medtech outlook — procurement-driven price compression, site-of-care migration, supply chain reconfiguration, GLP-1 adoption and platform competition — describe an industry reorganising around economics and infrastructure, not only clinical innovation.

For South Asia, the response cannot be limited to negotiating lower prices on imported technology. The more consequential agenda is structural: build quality systems that global buyers accept, harmonise regulation so that regional scale becomes possible, invest in clinical validation capacity, and develop the software and services layer where the region's talent base is genuinely competitive. Progress on those fronts would convert a period of global disruption into a durable position in the medical technology value chain.

---

Key Takeaways

• China's expanding VBP programme is influencing global device price expectations well beyond China, with direct implications for South Asian procurement benchmarks.
• The migration of procedures into outpatient and ASC settings changes device design requirements — favouring portable, simplified and single-use solutions suited to cost-constrained health systems.
• Supply chain diversification is the clearest industrial opening for South Asia, but progress depends on quality-system maturity, regulatory equivalence and supplier depth rather than cost alone.
• GLP-1 adoption is shifting care pathways and device demand unevenly across bariatric, diabetes, sleep apnea and cardiovascular categories; South Asia's metabolic disease burden makes this a market-structuring trend.
• Platform-based competition built on robotics, imaging, navigation and workflow software favours regions with strong software, data and clinical validation capacity.
• Regional regulatory harmonisation remains the single largest unaddressed constraint on South Asia's medical device competitiveness.

SEO Keywords

South Asia Economy, South Asia Business, Medical Devices, Medtech Trends, Foreign Direct Investment, Manufacturing, Supply Chain, Digital Economy, Artificial Intelligence, Regional Trade, Infrastructure, Industrial Development, Innovation, Investment, Emerging Markets, Regulatory Harmonisation, Healthcare Technology, Economic Development

Sources

• Clarivate, "5 medtech trends to watch in 2026," Life Sciences & Healthcare blog — https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026
• Clarivate, "Medtech Trends to Watch 2026" (report landing page) — https://clarivate.com/life-sciences-healthcare/lp/medtech-trends-to-watch-in-2026/